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Abstract
The poly (adenosine diphosphate (ADP)-ribosyl) polymerase inhibitors (PARPi) selectively kill cancer cells with
BRCA1 or BRCA2 (BRCA)-mutations. It has been proposed that cell death induction after PARPi depends on
unrepaired double strand breaks (DSBs) that accumulate due to the homologous recombination deficiency of
BRCA-mutated cells. Such accumulation of DSBs is inferred mainly from the high levels of DNA damage markers like
phosphorylated histone H2AX. Herein, we developed a model of isogenic cell lines to show that depletion of BRCA
causes PARPi-triggered cell death, replication stress (phosphorylated-H2AX and 53BP1 foci), and genomic instabil-
ity. However, persistent DSBs accumulation was not detected under the same experimental conditions. Hence, at
least in this cellular model, the trigger for cell death in PARPi-treated BRCA-depleted samples is not the accumula-
tion of unrepaired DSBs. Instead, cell death better correlates with a rapid and aberrant resolution of DSBs by er-
ror-prone pathways that leads to severe chromosomic aberrations. Therefore, our results suggest that in
PARPi-treated BRCA-deficient cells, chromosome aberrations may dually trigger both genomic instability and cell
death.
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Introduction
Homologous recombination (HR)-deficiency leads to
genomic instability due to the shift from “error-free” to “er-
ror-prone” DNA repair pathways (Prakash et al., 2015;
Talens et al., 2017). HR-deficiency is, therefore, a driver of
tumorigenesis as demonstrated in cancer cells deficient in
BRCA1- and BRCA2 (BRCA) expression or functions
(Fackenthal and Olopade, 2007; Ramus and Gayther,
2009). The HR-deficiency was also detected in BRCA1/2-
proficient cells. Such a condition is currently defined as
BRCAness of a tumor (Lord and Ashworth, 2016). The
BRCAness phenotype is frequently found in breast, ovar-
ian, pancreatic, prostatic, and other types of cancers (Ale-
xandrov et al., 2015; Holter et al., 2015; Robinson et al.,
2015; Waddell et al., 2015; Davies et al., 2017) . Given the
selective acquisition of BRCAness in tumors but not in
healthy cells, therapeutic targets that specifically kill HR-
deficient tumors but not proficient cells from patients were
explored. Such a synthetic lethality (SL) approach has al-
ready transcended from academic laboratories to pharma-
ceutical companies. Poly [adenosine diphosphate (ADP)-
ribosyl] polymerase inhibitors (PARPi) were developed to
selectively increase cell killing of HR-deficient cancer cells
sparing HR-proficient cells (Lord and Ashworth, 2017).
Notably, four PARP inhibitors are already available for
clinical use (Olaparib from AstraZeneca approved in 2015,
Rucaparib from Clovis approved in 2016, Niraparib from
TESARO/GSK approved in 2017, and Talazoparib from
Pfizer approved in 2018). Moreover, the optimization of
PARPi is still a subject of current research, and it is thus
possible that other PARPi will be approved for clinical use
in the near future (Sun et al., 2018).
Despite their current success in the clinical setting,
the mechanism of action of PARPi has only been partially
elucidated. While it is accepted that double-strand breaks
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(DSBs) are frequently formed in BRCA-deficient cells, the
trigger of such DNA lesions is a subject of debate. Ori-
ginally, the SL induced by PARPi was attributed to the in-
hibition of base excision repair (BER) (Bryant et al., 2005;
Farmer et al., 2005). PARPi-mediated inhibition of BER
was proposed to trigger DSBs when unresolved single-
strand breaks on DNA are encountered by replication forks
in S-phase. Such replication-associated DSBs are expected
to be toxic in the absence of HR. However, contrasting evi-
dence showed that BER deficiency, and even PARP knock-
out, do not recapitulate the phenotypes caused by PARPi
(Helleday, 2011). Instead, the trapping of the PARP en-
zymes in the regions of DNA damage seems to be the syn-
thetic lethal event triggered by PARPi. When encountered
by the replisome, such persistent PARP/DNA complex
triggers stalling, collapse and breakage of replication forks
into DSBs (Pommier et al., 2016). Hence, both previous
and current models suggest that the cause of SL triggered
by PARPi depends on the accumulation of DSBs.
A different line of evidence demonstrates that replica-
tion-associated DSBs are formed after PARPi treatment.
Chromosome aberrations generated at DSBs accumulate in
BRCA-depleted samples treated with PARPi (Farmer et
al., 2005). Moreover, the genomic signature of BRCAness
also requires DSB formation (Davies et al., 2017). How-
ever, the evidence of DSB persistency so far accumulated
in the literature is almost exclusively related to the analysis
of cells with H2AX, 53BP1, and Rad51 nuclear foci
(Bryant et al., 2005; Farmer et al., 2005; Rottenberg et al.,
2008; Jaspers et al., 2013; Johnson et al., 2013; Michl et al.,
2016). Here we use an isogenic system to downregulate ei-
ther BRCA1 or BRCA2 in colorectal cells, both of which
showed strong sensitivity to Olaparib. As reported in other
cellular models, the fraction of cells with numerous H2AX
and 53BP1 foci was upregulated in BRCA-depleted sam-
ples treated with Olaparib, and such replication stress was
followed by chromosome instability. However, the neutral
comet assay did not reveal a significant upregulation of
DSBs in Olaparib-treated BRCA samples. Together, these
results suggest that DSB formation but not its persistency
precede both cell death and genomic instability in Olaparib
treated BRCA-deficient cells.
Material and Methods
Cell lines and cell culture
HCT116p21-/- cells were generated (Bunz et al., 1998)
and kindly provided by B. Vogelstein. Cell culture was per-
formed in DMEM medium (Thermo Fisher Scientific) sup-
plemented with 10% FBS (GIBCO-NZ) and 1% penicil-
lin-streptomycin. Control for mycoplasma contamination
was performed periodically with a PCR-based method with
internal loading control. To generate cell lines expressing
fluorescent proteins, all the fluorescent proteins were ex-
pressed from the same backbone from Clontech as de-
scribed in Carbajosa et al. (2019). Briefly, transfection of
vectors encoding fluorescent proteins (piRFP- C1,
pECFP-C1, pmCherry-C1) was performed using JetPrime
(Polyplus-transfection) according to manufacturer’s ins-
tructions. After multiple rounds of cell sorting (3-5) per-
formed with FACS Aria II (BD bioscience), stable cell line
pools expressing the different fluorescent proteins were es-
tablished. The resulting cell lines pools were transduced
with control, shBRCA1, and shBRCA2 using titers that
promoted the higher downregulation BRCA1 and BRCA2
by qPCR and WB, yet keeping similar proliferation rates to
the shSCR-transduced cell lines. Our goal here was to avoid
clonal selection, which is often an issue that could result in
misleading conclusions when generating stable cell lines.
shSCR, shBRCA1, and shBRCA2 cell lines were used for
experimentation for no more than six passages after the es-
tablishment of the cellular pools.
DNA constructs and shRNA
shBRCA1 (TRCN0000010305, Sigma-Aldrich) and
shBRCA2 (Carlos et al., 2013), were cloned into pLKO.1-
TRC vector through EcoRI and AgeI restriction sites; and
shSCR-pLKO.1 was previously described (46). shSCR-
plenti (TR30021), was acquired from Origene.
Antibodies
Primary antibodies used were: -BRCA1 (Oncogene
Research), KU70 (Abcam),  H2AX Ser 139, Upstate
(Millipore, clone JBW301),  53BP1 (Santa Cruz). Sec-
ondary antibodies used were Anti-mouse IgG (Sigma-Al-
drich A 4416) for western blot analysis and -mouse/rab-
bit-conjugated Cy2/Cy3 antibodies (Jackson Immuno
Research) for immunofluorescence assays. Nuclei were
stained with DAPI (Sigma).
Cell counting methods
Cells were seeded on 96-well dishes at a density of
1500 cells/well. Cells were fixed with 2% paraformal-
dehyde/sucrose. InCell 2200® was used to obtain images
of DAPI-stained nuclei and an InCell Analyzer WorkSta-
tion® was used to count nuclei. Alternatively, the number
of viable HCT116 p21-/- shBRACA1/2 and shSCR cells
was determined with a CellTiter-Glo® Luminescent Cell
Viability Assay G-7570 (Promega), according to the manu-
facturer’s instructions. When assessing growth rates, cells
stably expressing iRFP were seeded in 96-well plateat
2x103cell/well and plates were scanned daily in the Odys-
sey Clx System (LI-COR Biosciences) as previously re-
ported (Hock et al., 2014). For flow cytometry experi-
ments, isogenic cell populations were counted using a
Countess FL device (Thermo Fisher) previous to plating
the co-cultures.
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Co-cultivation method
Transfection protocols were performed using
JetPrime (Polyplus-transfection) according to the manufac-
turer’s instructions. Multiple rounds of cell sorting (3-5)
were performed (FACS Aria II, BD Bioscience) to select
pools that express CFP, iRFP, and mCherry fluorescent
proteins. Each “colored” cell line was sub-sequentially
used to generate shSCR, shBRCA1, and shBRCA2 ex-
pressing pools (Carbajosa et al., 2019). The transduced
cells that showed the higher downregulation of BRCA1 and
BRCA2 by qPCR and WB, yet keeping similar prolifera-
tion rates to the shSCR-transduced cell lines, were selected
for survival assays. Equal amounts of cells were plated in a
single 96 well ensuring ~33% distribution for each cell line.
As a consequence of the equal proliferation rate, such dis-
tributions were conserved at the endpoint, which took place
6 days later. SL treatment alters the composition in a way
that the proportion of shSCR increases and the shBRCA1
and shBRCA2 decrease.
Cell cycle analysis
Cells were fixed with ice-cold ethanol and re-sus-
pended in PBS containing RNase I (100 mg/mL, Sigma)
and propidium iodide (50 mg/mL, Sigma). Samples were
subjected to fluorescence-activated cell sorting (FACS, Ca-
libur, Becton Dickinson), and data were analyzed using the
Summit 4.3 software (DAKO Cytomation) as previously
described (Federico et al., 2016).
Protein analysis
For direct western blot (WB) analysis, samples were
lysed in commercial Laemmli buffer (Bio-Rad) contining
the reducing agent 2-mercaptoethanol. ECL detection
(Amersham, GE Healthcare) was performed according to
the manufacturers’ instructions. Western blot images were
taken with Image QuantLAS4000 (GE Healthcare), which
allows capture and quantification of images within a linear
range.
Quantitative RT-PCR
Cells were lysed and total RNA was extracted using
TRIzol® Reagent (Invitrogen). Reverse transcription was
performed andBRCA2mRNA levels were measured with
Fw-5’-AGGGCCACTTTCAAGAGACA3’ and Rv-
5’TAGTTGGGGTGGACCACTTG3’ primers using the
iQ SYBR Green Supermix (Invitrogen). Relative expres-
sion levels were normalized to GAPDH.
Immunostaining and microscopy
Cells were fixed in 2% (w/v) paraformaldehyde
(PFA)/2% sucrose and permeabilized with 0.1% (v/v) Tri-
ton X-100 in phosphate buffered saline (PBS). Blocking
during 2 h at RT in PBS 2% (v/v) donkey serum (Sigma)
was performed. Coverslips were incubated for 1 h in pri-
mary antibodies and then 1 h in secondary antibodies. Im-
ages were obtained with a Zeiss Axioplan confocal micro-
scope or a Zeiss Axio Imager.A2. A total of 250-300 nuclei
were analyzed per sample following the procedure de-
scribed in (Mansilla et al., 2016).
Chromosomal aberration analysis
Metaphase chromosome spreads were generated in-
troducing minor modifications to protocols previously used
by us (Federico et al., 2016). Before harvesting, cells were
treated with Colcemid (0.08 g/mL, KaryoMAX, Invi-
trogen) for 3 h. Cell pellets were incubated in hypotonic
buffer (KCl 0.0075 M) at 37 °C for 4 min, followed by fixa-
tion in Carnoy’s fixative (3:1 methanol: glacial acetic acid).
Cells were dropped onto slides and air-dried before staining
with 6% (w/v) Giemsa in Sorensen’s buffer (2:1 67 mM
KH2PO4 : 67 mM Na2HPO4, pH 6.8) for 2 min. 70 meta-
phase spreads were evaluated to detect gaps, breaks, and
exchanges using an Applied Imaging Cytovision (2.10.17
version, Leica).
Micronucleus (MN) assay
Cells seeded at low density were treated. Micronuclei
analysis was performed using protocols previously descri-
bed previously by us (Federico et al., 2016). Samples were
incubated with cytochalasin B (4.5 g/mL, Sigma) for 36 h.
Cells were washed for 1 min with hypotonic buffer (KCl
7.5 mM), twice with PBS and fixed with PFA/sucrose 2%
for 20 min. DAPI staining served to visualize whole cells
and nuclei respectively. 300 binucleated cells were ana-
lyzed and the frequency was calculated as MN/binucleated
cells.
Neutral comet assay
We used protocols previously described by Murfuni
et al. (2013) with some modifications. Briefly, cells were
embedded in 0.5% low-melting agarose on a slide and
treated with a lysing solution (EDTA 30mM, SDS 0.5%)
for 10 min at 4 °C. Slides were washed twice with deio-
nized water (ddH2O), immersed in TBE 1X and subjected
to electrophoresis at 17 V (6-7 mA) during 5 min at 4 °C.
Samples were washed with ddH2O and stored in methanol
overnight DNA was stained with propidium iodide and
samples were examined with a Zeiss fluorescence micro-
scope. To determine the tail moment (tail length x fraction
of total DNA in the tail), 100-150 nuclei were evaluated per
each condition using the OpenComet program.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 5.0 (GraphPad Software), applying the Student’s
t-test and ANOVA test as appropriate. Graphs were gener-
ated using the same software.
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Results
Downregulation of BRCA1 or BRCA2 levels
sensitizes HCT116 colorectal cancer cells to
Olaparib treatment
Generating BRCA-deficient cell lines by stable
knockdown is a difficult process, as most cells do not sur-
vive in the long term. The main limitation to reach stable
BRCA depletion is the abrupt proliferation arrest that fol-
lows a severe knockdown or depletion of BRCA (Feng and
Jasin, 2017). In order to achieve an efficient knockdown of
BRCA proteins, we set up an shRNA-based downregu-
lation of BRCA1 or BRCA2. Many cell lines did not re-
cover after an acute crisis, and other cell lines regained
BRCA expression after a few passages (Carbajosa et al.,
2019). We then explored colorectal cancer cells that are not
characterized by a high frequency of BRCA loss. We chose
a modified HCT116 cell line lacking the cyclin kinase
inhibitor p21 that, therefore, has an attenuated G1/G2
checkpoint (Bunz et al., 1998), which could favor the estab-
lishment of stable BRCA-deficient cells. It should be also
mentioned that p21 deficiency negatively regulates
BRCA2-mediated repair of replication-coupled DSBs
(Mauro et al., 2012), which could be relevant for controling
BRCA1 deficient but not BRCA2 deficient cells. As de-
scribed in the methods sections we set up a protocol that ef-
ficiently downregulated BRCA1 and BRCA2 (Figure 1A).
In contrast to other cells lines tested, HCT116p21-/- showed
similar proliferation rates on BRCA-proficient and
BRCA-deficient cells (Figure 1B). Flow cytometry analy-
sis showed a strong BRCA1/2-related cell cycle arrest and
subG1 accumulation in BRCA-depleted samples (Figure
1C). Synthetic lethality (SL) induction after Olaparib treat-
ment was observed at 6 days post-Olaparib treatment in sin-
gle cultivation methods and co-cultivation experiments
(Figure 1D-G). The SL correlated with the efficiency of
BRCA1 downregulation, reaching a critical level at pas-
sage 10 (Figure 1H). Hence, colorectal cancer cells, which
do not frequently lose BRCA, can be sensitized to Olaparib
by BRCA knockdown.
Olaparib-triggered cell death in BRCA-deficient
samples is preceded by the accumulation of markers
of double-strand break formation and repair
Many reports indicate that the treatment of BRCA-
deficient cells with PARPi triggers an acute increase of rep-
lication stress that leads to the accumulation of DSBs. Such
DSBs were frequently revealed as H2AX foci formation in
the nucleus of PARPi-treated cells (Bryant et al., 2005;
Farmer et al., 2005; Rottenberg et al., 2008; Jaspers et al.,
2013; Johnson et al., 2013; Michl et al., 2016). In our ex-
perimental settings, the percentage of cells with high levels
of H2AX foci significantly increased at 2 days after Ola-
parib treatment (Figure 2A,B), which is in agreement with
previous reports. The percentage of cells with H2AX de-
creases after that time, reaching levels that are similar to
those of untreated conditions at 6 days (not shown). The lo-
calization of 53BP1 to nuclear foci also increased in the
same experimental conditions and at 48 hours after Ola-
parib treatment (Figure 2C,D). Such observations sugges-
ted that in HCT116p21-/- cells depleted from BRCA proteins,
acute replication stress precedes the cell death triggered by
PARPi. Moreover, the rapid recruitment of 53BP1 to such
DSBs indicates that DSBs could be rapidly repaired by a
53BP1-driven repair.
Olaparib-triggered cell death in BRCA-deficient
HCT116p21-/- is preceded by accumulation of
chromosome instability
In the context of BRCA-depletion, 53BP1 favors the
repair of DSBs by non-homologous end joining (NHEJ)
(Daley and Sung, 2014). Since PARPi-induced DSBs are
actually one-ended DSBs formed at the tip of collapsed rep-
lication forks, the NHEJ-mediated processing of such
DSBs indefectible causes formation of radial chromosomes
and increase other types of chromosome instability (Fede-
rico et al., 2018). In agreement with results obtained in
mammary and ovarian models, the depletion of BRCA pro-
teins in HCT116p21-/- colorectal cancer cells cause massive
genomic instability after Olaparib treatment. Such genomic
instability was manifested as the extensive accumulation of
gaps, breaks, radial chromosomes (Figure 3A,B) and mi-
cronuclei (Figure 3C,D), which are all markers of aberrant
repair of DSBs (Federico et al., 2018). Together these ex-
periments show that a steep increase in genomic instability
temporally precedes cell death in PARPi-treated
HCT116p21-/- cells.
Olaparib-triggered cell death in BRCA-deficient
samples is not preceded by persistent double-strand
breaks
While the accumulation of cells with H2AX foci is
accepted as a marker of DSB accumulation in many
PARPi-related studies, experts in the field have addressed
the limitations of such markers (Zellweger et al., 2015). In-
triguingly, the maximum percentage of cells with H2AX
foci was observed at 2 days after Olaparib treatment (Fig-
ure 2B) although cell death was negligible even at 3 days
after Olaparib treatment (Figure 1C). Hence, we wondered
whether DSBs formed at the time of maximal H2AX de-
tection would accumulate for a long time to eventually trig-
ger cell death days later. We reasoned that direct detection
of DSBs should be set up, and so we optimized the neutral
comet assay to be used in our experimental conditions.
Bleomycin was used as a positive control to observe the ac-
cumulation of DSBs in HCT116p21-/- cells (Figure 4A). Sur-
prisingly, DSBs were not detected by neutral comet assay
after Olaparib treatment in both BRCA-deficient cell lines
(Figure 4B,C). Ruling out the possibility of a delayed accu-
mulation of DSBs, the neutral comet assay did not reveal
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Figure 1 - BRCA1 and BRCA2 downregulation sensitize colorectal cancer HCT116p21-/- cells to Olaparib treatment. A) HCT116p21-/- were transduced
with control (shSCR_scramble) and shRNA vectors specific for BRCA1 and BRCA2 (shBRCA1 and shBRCA2). Western blot and RT-qPCR showing
the levels of BRCA1 and BRCA2 protein and mRNA, respectively, at passage 4 after transduction. B) Growth curves of untreated samples. Data are
shown as mean  SD from 5 independent experiments. C) Flow cytometry of propidium iodide-stained samples. D) Representative panels depicting the
SL induced in the HCT116p21-/- cells after BRCA downregulation. Samples were stained with DAPI and photographs were obtained after automatic cap-
ture. E-F) HCT116 p21-/- cells transduced with shSCR and shRNA vectors specific for BRCA1 and BRCA2 (shBRCA1 and shBRCA2) were plated at a
density of 1500 cells/well in 96 well plates. Six days later, samples were counted with direct (automatized cell counter-E) and indirect (F-cell titer Glo)
methods. The plot shows the quantification (mean  SD) of the surviving fraction of 3 independent experiments. G) HCT116p21-/- cells were transduced
with fluorescent proteins to generate colored pools as described in the material and methods section. After shRNA transduction, samples were co-cultured
and treated with Olaparib when indicated. The plot shows the quantification of the surviving fraction of 3 independent experiments. H) Synthetic lethality
(SL) is lost with increasing cell passages (mean  SD, n= 2). Western blot showing BRCA1 levels at different times post shRNA transduction. Numbers
below each lane are the quantification of normalized BRCA1 levels. Cell number was determined at the indicated passages and the SL was calculated.
Statistical analysis was performed using two-way ANOVA with Bonferroni post-hoc test and differences were considered significant with p  0.001. The
letters above the different values indicate groups that are significantly different.
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Figure 2 - The number of cells with H2AX and 53BP1 foci in BRCA-depleted HCT116p21-/- cells increases after Olaparib treatment. A) HCT116p21-/-
cells transduced with shSCR, shBRCA1, and shBRCA2 cells were treated with Olaparib. After 48 h, immunostaining with -H2AX antibodies was per-
formed. The percentage of cells with foci was quantified using fluorescence microscopy (magnification: 100X). Nuclei with more than 35 H2AX focal
structures were considered positive. At least 300 cells per condition were analyzed in 5 independent experiments. Statistical analysis was performed using
Two-way ANOVA with Bonferroni post-hoc test (***p  0.001). Data are shown as mean  SD. B) Representative images of data showed in A. Zoom im-
ages of the nuclei indicated with the yellow dotted square are showed on the left. C) HCT116p21-/- shSCR and shBRCA1 cells were treated with Olaparib.
After 48 h, immunostaining with a 53BP1 antibody was performed. The percentage of cells with foci was quantified using fluorescence microscopy (mag-
nification: 100X). Only nuclei with more than five 53BP1 foci were quantified as positive. At least 300 cells per condition were analyzed and data are
shown as mean  SD from5 independent experiments. D) Representative images of data showed in C. Zoom images of the nuclei indicated with the yel-
low dotted square are showed on the left. Statistical analysis was performed using Two-way ANOVA with Bonferroni post-hoc test and differences with p
 0.001 were considered significant. In all graphs, the letters above the different values indicate groups that are significantly different.
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Figure 3 - Chromosome instability precedes Olaparib-triggered cell death in BRCA-deficient HCT116p21-/-. A) HCT116p21-/- cells transduced with
shSCR, shBRCA1 and shBRCA2 were submitted to cytogenetic analysis 48 h after the treatment with Olaparib. The frequency of gaps, breaks, and ex-
changes was calculated after analyzing a minimum of 70 metaphases per condition in 5 independent experiments. B) Representative images of
chromosomic aberrations quantified in A. C) HCT116p21-/- transduced with shSCR, shBRCA1 and shBRCA2 were treated for 24 h with Olaparib and
were arrested at a binucleated stage using cytochalasin B. The frequency of micronuclei was estimated (shown as mean  SD, using DAPI staining and
fluorescence microscopy (magnification: 100X), analyzing a minimum of 300 binucleated cells per condition in 4 independent experiments. D) Repre-
sentative images of chromosomic aberrations quantified in C. Statistical analysis was performed using two-way ANOVA with Bonferroni post-hoc test
and differences were considered significant with p  0.001. The letters above the different values indicate groups that are significantly different.
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Figure 4 - Persistent double-strand break accumulation does not precede Olaparib-triggered cell death in BRCA-deficient HCT116p21-/- cells. A)
HCT116p21-/- cells transduced with shSCR, shBRCA1 and shBRCA2 were submitted to neutral comet assay in untreated and Bleomycin-treated condi-
tions (mean +SD, n= 2). B) HCT116p21-/- cells transduced with shSCR, shBRCA1 and shBRCA2 were submitted to neutral comet assay two days after
Olaparib treatment, which coincides with the maximum levels of H2AX accumulation. Results are representative of 2 independent experiments. C)
HCT116p21-/- cells transduced with shSCR and shBRCA1 were submitted to neutral comet assay at the indicated days after Olaparib treatment. Results are
representative of 2 independent experiments. Statistical analysis was performed using One Way ANOVA with Dunns comparison test and differences
were considered significant with p  0.05. The bars on top of the distribution clouds indicate the median. The letters above the different values indicate
groups that are significantly different.
DSBs at any time points after Olaparib treatment (Figure
4C). Together, these results demonstrate that persistent ac-
cumulation of DSBs is not frequent in Olaparib-treated
BRCA-deficient HCT116p21-/-cells. Hence, cell death is un-
likely triggered by unrepaired DSBs in these settings. In-
stead, DSBs may indirectly trigger cell death in a manner
that depends on the accumulation of unstable chromosomes
generated by dysregulated error-prone pathways (Figure
5). Together, these results show that genomic instability
and cell death are intimately associated with BRCA-
deficient HCT116p21-/- cells treated with PARPi. The impli-
cations of these findings for the acquisition of resistance in
PARPi treated BRCA cancers will be discussed below.
Discussion
The accumulation of unrepaired DSBs is considered
to be the trigger of cell death in BRCA-deficient cells
treated with PARPi (Bryant et al., 2005; Farmer et al.,
2005). However, at least in the isogenic cellular model pre-
sented in this study, BRCA-depletion triggered cell death
and chromosome instability but not detectable DSB accu-
mulation. Such a finding suggests that the cause of cell
death in this scenario is not mainly associated with the per-
sistence of unrepaired DSBs, but with the accumulation of
other triggers of cell death, possibly resulting from the type
of DNA repair pathway chosen for DSB repair.
DSBs repair pathway choice as a trigger of cell
death in PARPi-treated BRCA1/2 deficient cells
The acquisition of resistance to PARPi has been
mainly linked to the dysregulated activation of error-prone
repair pathways in BRCA-deficient cells (Lord and
Ashworth, 2013). However, other mechanisms of resis-
tance were also described. An indirect mechanism reported
was the increased expression of genes that encode for the
drug efflux transporter P-glycoprotein (Rottenberg et al.,
2008). Furthermore, the recovery of HR capacity (e.g., re-
version of primary mutations or secondary mutations that
restore BRCA function) promotes resistance to Olaparib
(Edwards et al., 2008; Sakai et al., 2008; Swisher et al.,
2008; Norquist et al., 2011). The loss of proteins that facili-
tate NHEJ activation, such as 53BP1, also promote resis-
tance to PARPi and restoration of HR (Bunting et al., 2010;
Jaspers et al., 2013). PTEN and Rev7 loss were additionally
described as mechanisms of resistance driven by HR resto-
ration (Peng et al., 2014; Xu et al., 2015). Besides the re-
covery of HR, stabilization of the replication fork by a
limitation of exonuclease activity of MRE11 was reported
as a trigger for PARPi resistance in BRCA-deficient back-
grounds (Ray Chaudhuri et al., 2016; Rondinelli et al.,
2017). Hence, PARPi resistance is linked to both the
amount of DSBs formed and the loss of HR.
There is much less available evidence supporting that
the dysregulation in DSBs repair also influences the extent
of cell death caused by PARPi. The choice of alternative
end joining (Alt-EJ) prevents cell death in PARPi-treated
BRCA1-deficient cells (Ceccaldi et al., 2015). Conversely,
the elimination of pol  prevents ALT-EJ and increases cell
death (Ceccaldi et al., 2015). It is currently unknown
whether such cell death is associated with the accumulation
of persistent DSBs, or whether it depends on the HR-
independent resolution of DSBs. Another factor to take into
consideration when evaluating variables that influence the
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Figure 5 - Model depicting the implications of low DSB accumulation after PARPi in BRCA-deficient cells. In BRCA-deficient cells, Olaparib treatment
causes replication fork collapse. In rare samples, DSBs may accumulate and such a persistent load of DSBs may trigger cell death (left outcome). How-
ever, in most samples, DSBs are processed by error-prone pathways, such as non-homologous end joining (NHEJ) and alternative end joining (ALT-EJ).
Error-prone pathways such as ALT-EJ, may not induce aberrant re-arrangement of chromosomes and may promote cell survival (middle outcome - see
discussion). Other error-prone pathways that cause chromosome re-arrangement correlate with decreased cell survival (right outcome - see discussion).
survival of BRCA-deficient cells treated with PARPi is
fork stabilization. ALT-EJ promotes fork stabilization and
prevents its excessive processing (Kais et al., 2016). Hen-
ce, the repair of DSBs via ALT-EJ promotes the survival of
BRCA-deficient cells treated with PARPi. Intriguingly, the
NHEJ-mediated repair of DSBs has the opposite effect on
cell death induction. As a consequence of HR restoration,
53BP1 and Rev7 loss increases cell survival of PARP
treated cells (Bunting et al., 2010; Jaspers et al., 2013; Xu
et al., 2015). It is therefore difficult to establish a causal
link between chromosome instability and cell death. How-
ever, there are several correlations that put such a case into
consideration. For example, FANCD2 loss increases both
cell death and chromosome instability of BRCA2-deficient
cells (Michl et al., 2016). In addition, EZH2 depletion in-
duces survival and prevents genomic instability in
BRCA2-deficient tumors in a manner that depends on
Mus81 loading to replication forks (Rondinelli et al.,
2017). PTIP loss also reduces both cell death and chromo-
some instability in BRCA1-deficient samples treated with
PARPi, in this case without restoring HR (Ray Chaudhuri
et al., 2016). Moreover, expression of the micro RNA
miR-493-5p affects the survival of PARPi-treated
BRCA2-mutated/depleted cells by modulating the levels of
nucleases involved in maintaining genomic stability and
without affecting HR (Meghani et al., 2018). Therefore,
chromosome instability and cell death concomitantly occur
in PARPi treated BRCA-deficient cells. As chromosome
instability temporally precedes cell death it could be pro-
posed that the trigger for cell death is a toxic upregulation
of chromosomic instability. In fact, in the context of ATM
deficiency, PARPi also induces cell death, which has been
attributed to the accumulation of toxic NHEJ-generated ab-
errant chromosomes (Balmus et al., 2019). Intriguingly, in
such experimental settings, ATM-deficient cells do not ac-
cumulate DSBs, as revealed by a neutral comet assay (Bal-
mus et al., 2019). Hence, as in ATM-deficient cells,
BRCA-deficient cells may die because of toxic chromo-
some instability triggered by PARPi.
Proofs of DSBs accumulation in BRCA-deficient
cells treated with PARPi
Few assays can directly reveal DSBs, and such assays
may not be very sensitive to low levels of DSBs. However,
both pulse field gel electrophoresis (PFGE) and neutral
comet assays can reveal DSBs reported to take place in
HR-proficient settings (Elvers et al., 2012; Murfuni et al.,
2013; Federico et al., 2016; Quinet et al., 2016). Such re-
sults suggest that the assays should be sensitive enough to
detect DSBs in the context of HR-deficient cells. Intrigu-
ingly, such techniques were only rarely applied to BRCA-
deficient cells treated with PARPi (Clements et al., 2018;
Gogola et al., 2018). To our knowledge, this is the first re-
port that uses a direct DSB detection method to explore the
effect of the PARPi treatment on BRCA-depleted cells
(without the addition of other genotoxins). Instead of using
direct DSBs detection, the PARPi field has chosen to focus
its attention on the accumulation of H2AX nuclear foci as
a marker of DSBs. Whether H2Ax nuclear foci strictly
correlate with DSBs accumulation is a subject of debate.
Some laboratories have attempted to combine it with
53BP1 colocalization and to obtain independent evidence
of DSBs formation, such as the accumulation of pATM and
pKap1 (Berti et al., 2013; Zellweger et al., 2015; Federico
et al., 2016; Perkhofer et al., 2017). However, the proof of
DSBs formation is strictly dependent on the detection of
such DNA lesions in PFGE or neutral comet assays. Multi-
ple lines of evidence demonstrate that DSBs are formed af-
ter the PARPi treatment of BRCA-deficient samples. Most
chromosome aberrations, as well as micronuclei, can only
be formed from DSBs (Federico et al., 2018). Moreover,
the BRCAness signature is also associated with DSBs for-
mation (Davies et al., 2017). That being said, our data indi-
cate that while DSBs are generated, they are not persistent
enough to be the trigger for cell death as suggested by the
currently accepted mode of action of PARPi. We hypothe-
size that DSBs are frequently formed but rapidly repaired
by end-joining-mediated pathways after PARPi treatment.
Perhaps in the future this hypothesis could be further evalu-
ated by the modification of methods such as the NHEJ host
reactivation assay, which needs to be adjusted according to
the characteristics of PARPi-triggered DSBs (Nagel et al.,
2014). At least in this scenario, H2AX nuclear foci may
rather reveal sites where DSB repair has occurred and sites
of unresolved DSBs. These findings, therefore, suggest
caution in the interpretation of H2AX foci data, a limita-
tion that may extend to the analysis of other nuclear foci in
the DNA damage response field.
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